AI assistant
Dechra Pharmaceuticals PLC — Remuneration Information 2018
Sep 17, 2018
4797_rns_2018-09-17_d52b3e06-d753-4e3e-ba06-bacd6e34b14b.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 9585A
Dechra Pharmaceuticals PLC
17 September 2018
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 17 September 2018
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Long-Term Incentive Scheme | |||
| Period of return: | From: | 15 March 2018 | To: | 14 September 2018 |
| Balance of unallotted securities under scheme(s) from previous return: | 249 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 156,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | Nil | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 156,249 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 17 September 2018
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Approved Share Option Scheme | |||
| Period of return: | From: | 15 March 2018 | To: | 14 September 2018 |
| Balance of unallotted securities under scheme(s) from previous return: | 22,214 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 2,745 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 19,469 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 17 September 2018
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | Unapproved Share Option Scheme | |||
| Period of return: | From: | 15 March 2018 | To: | 14 September 2018 |
| Balance of unallotted securities under scheme(s) from previous return: | 73,706 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 36,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 19,266 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 90,440 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 17 September 2018
| Name of applicant: | Dechra Pharmaceuticals PLC | |||
| Name of scheme: | SAYE Scheme | |||
| Period of return: | From: | 15 March 2018 | To: | 14 September 2018 |
| Balance of unallotted securities under scheme(s) from previous return: | 5,622 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 14,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 5,968 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 13,654 | |||
| Name of contact: | Melanie Hall |
| Telephone number of contact: | 01606 814 730 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BLRLIFIAALIDLIT